Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.01 - $6.33
Previous CloseN/A
Volume51.94M
Average Volume (3M)4.35M
Market Cap
$444.08M
Enterprise Value$201.66M
Total Cash (Recent Filing)$117.46M
Total Debt (Recent Filing)$7.25M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Nov 05, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding149,522,640
10 Day Avg. Volume4,599,725
30 Day Avg. Volume4,347,258
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue48.73
Enterprise Value/Gross Profit-66.25
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$7.22Price Target Upside143.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PositionAbsci raised significant funds through a secondary offering and an ATM transaction, extending its cash runway into a future period.
Market PotentialThe opportunity for an effective injectable hair loss therapy is promising, especially with limited treatments offering durable efficacy.
PartnershipsManagement anticipates at least one partnership from a large pharma company, which could provide a source of non-dilutive capital.
Bears Say
Financial PerformanceAbsci reported lower-than-expected revenues and a larger net loss per share for 2Q25 compared to consensus estimates.
Market CompetitionABS-101 is on track for initial data, which should provide a key first look at the TL1A asset's positioning within the increasingly competitive TL1A landscape.
Product ChallengesMinoxidil can cause irritation, dandruff, and brittle hair, while oral minoxidil comes with risks of low blood pressure and increased heart rate.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.01 and its highest was $6.33 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $444.08M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Nov 05, 2025 which is in 35 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Aug 12, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.209 by -$0.031.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.2.
How many shares outstanding does AbSci have?
AbSci has 149,522,640 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.209. Following the earnings report the stock price went up 5.051%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.22 (143.10% Upside)
$7.22 (143.10% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 66%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $433.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.18%
12-Months-Change
Fundamentals
Return on Equity
-57.39%
Trailing 12-Months
Asset Growth
-17.86%
Trailing 12-Months
Company Description
AbSci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and strategic partnerships, strengthening Absci's financial position and enhancing its drug development capabilities. However, the increase in R&D expenses and low revenue figures present challenges that need to be addressed.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$7.22
▲(143.10% Upside)
Technical Analysis
Autolus Therapeutics
―
RAPT Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
7.73% Insiders
19.70% Mutual Funds
21.33% Other Institutional Investors
35.64% Public Companies and
Individual Investors